Advancements in research have led to the steady decline of breast cancer mortality over the
past thirty years. However, breast cancer incidence has continued to rise, resulting in an …

The glucocorticoid receptor (GR) is a major nuclear receptor (NR) drug target for the
treatment of inflammatory disorders and several cancers. Despite the effectiveness of GR …

The lipid metabolism adaptations of estrogen and progesterone receptor-positive breast
cancer tumors from a mouse syngeneic model are investigated in relation to differences …

Importance Adenomyosis is a common chronic gynecological disorder, and its treatment is
an unmet need. New therapies need to be developed. Mifepristone is being tested for …

Triple-negative breast cancer (TNBC) is an aggressive subtype of breast cancer that lacks
expression of the nuclear steroid receptors that bind estrogens (ER) and progestogens …

Recent advances have brought forth the complex interplay between tumor cell plasticity and
its consequential impact on drug resistance and tumor recurrence, both of which are critical …

Breast cancer is the most frequently diagnosed cancer in women with a high incidence and
mortality worldwide. Nearly 70% of breast carcinomas express steroid hormone receptors …

The glucocorticoid receptor (GR) is a major nuclear receptor (NR) drug target for the
treatment of inflammatory disorders and several cancers. Despite the effectiveness of GR …

Estrogen receptor positive (ER+) breast cancer is the most common breast cancer
diagnosed annually in the US with endocrine-based therapy as standard-of-care for this …

The development of antiprogestins was initially a gynecological purpose. However, since
mifepristone was developed, its application for breast cancer treatment was immediately …